Conformal RT Shows Good Survival Rates In Michigan Study of Localized Prostate Cancer

Oncology NEWS InternationalOncology NEWS International Vol 5 No 1
Volume 5
Issue 1

MIAMI BEACH--Early-stage prostate cancer patients treated with three-dimensional conformal radiotherapy (3D-CRT) at the University of Michigan Medical Center had excellent survival rates with few complications, Howard Sandler, MD, reported at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting.

MIAMI BEACH--Early-stage prostate cancer patients treated withthree-dimensional conformal radiotherapy (3D-CRT) at the Universityof Michigan Medical Center had excellent survival rates with fewcomplications, Howard Sandler, MD, reported at the American Societyfor Therapeutic Radiology and Oncology (ASTRO) meeting.

The use of 3D-CRT allows radiation oncologists to better focusthe radiation treatments to all angles of the prostate and thusgive higher radiation doses to the tumor while preserving normaltissues, Dr. Sandler said. The technique creates dose distributionsbased on anatomic data derived from computed tomography (see imageon page 1).

Dr. Sandler, associate professor and director of clinical programsat the Ann Arbor center, said that the study involved 707 patientswith localized prostate cancer treated with 3D-CRT. The mediantotal radiation dose was 69 Gy. Excluded from the study were patientswho were node positive, who had undergone post-prostatectomy radiotherapy,or who had received preradiation androgen ablation.

For analysis, patients were divided into two subgroups: favorable(those with preradiation PSA levels of 20 or below and early-stagetumors) and unfavorable (later-stage disease and higher PSA levels).The favorable group included a surgical subset (109 patients)restricted to patients with PSA less than 10 and age below 70.Patients have been followed for up to 8 years (median, 36 months).

The favorable subgroup patients had an 87% disease-free survivalrate at 5 years. In the unfavorable group, only 22% were diseasefree at 5 years, emphasizing the importance of early detection,Dr. Sandler said. Five-year survival for the surgical group was83%.

"In addition to the excellent survival rates for favorablepatients, the complication rates for all patients in our studywere very low--3% or less," Dr. Sandler said. The risk ofgrade 4 complications was only 0.5%.

Preradiation PSA level proved to be the most critical predictorof treatment success, he said. At 5 years, those with preradiationPSA levels below 4 had an 87% disease-free survival rate; thosewith PSA levels between 4 and 10 had a 72% survival rate; PSA10 to 20, a 37% survival rate, and PSA greater than 20, a 26%survival rate.

In an interview with Oncology News International, Dr. Sandlerdescribed the work as a "benchmark study, showing where westand with this treatment at the University of Michigan."

NCI Study Underway

He noted that the National Cancer Institute is funding a phaseI/II dose-escalation study of 3D-CRT in prostate cancer patients.Currently underway at nine institutions, including the Universityof Michigan, and headquartered at Washington University in St.Louis, the study has enrolled about 125 patients to date.

Dr. Sandler added that since treatment with 3D-CRT appears tobe superior to conventional radiotherapy, phase III trials willprobably involve randomization between different doses of radiationdelivered via 3D conformal techniques rather than between 3D-CRTand conventional techniques.

Dr. Sandler's colleagues in the study were P. William McLaughlin,MD, and Kathleen Kish of the University of Michigan and ProvidenceHospital.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Related Content